New hope for rare blood vessel disorders: everolimus trial launches
NCT ID NCT07477548
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug everolimus in 67 people with vascular anomalies (abnormal blood vessels) that haven't responded to standard treatments. The goal is to shrink the lesions and improve symptoms. Participants take everolimus daily for 6 months, with doses adjusted by age and other medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Everolimus (a drug that blocks a protein called mTOR, which helps control cell growth)
What this could lead to
If it works, this could offer a new treatment option for people with severe vascular anomalies that haven't responded to other therapies.
What could go wrong
This is an early phase 2 trial with no control group, so results are uncertain. Everolimus can cause side effects like mouth sores, infections, and metabolic changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••